PI PHARMA
ActiveSummary
PI PHARMA has been active since 2006 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show negative equity (-€161,750) and a net result of €174,639. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 8% of 6,141 sector peers (NACE 46, financial year 2025). The computed 12-month bankruptcy probability is 1.4% (low).
Directors
Board 2
Permanent representatives 1
Statutory auditor 1
Not every act has been read: a resignation may still be missing
Mandate history
- Board
- Statutory auditor
- began earlier
| Name | Functions and periods |
|---|---|
| Nikka Management BV |
|
| Jordan Chir |
|
| EY Bedrijfsrevisoren BV |
|
| DELOITTE Bedrijfsrevisoren BV |
|
| LMDC GmbH |
|
| HFS BV |
|
Owners and capital
Owners
2 ownersChain of control
- Abacus Medicine A/SDK
- A.forall Group
- MEDIGROUP
- PI PHARMA
Highest known parent: Abacus Medicine A/S (Denmark). The sources do not say who stands above it.
Owners 2
- MEDIGROUPparentSourceaccounts MEDIGROUP 2025100%
- Abacus Medicine A/SDKconsolidating parentconsolidates
Sources: the companies' annual accounts, the acts in the Belgian Official Gazette and the LEI register. Annual accounts state the shareholders that notified the company under article 7:225 of the Code of Companies and Associations and the parent companies that consolidate it. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not include these statements in its annual accounts, or does not have to, is not listed.